Shiseido has signed a binding agreement to sell its Chinese subsidiary, Shiseido Liyuan Cosmetics (SLC), to a consortium led by Hong Kong-headquartered private equity firm IDG Capital. SLC manufactures and sells the Aupres brand in China, and the transfer covers the whole company.
The deal is expected to complete between the fourth quarter of 2026 and the first quarter of 2027, subject to regulatory approvals including in China. Shiseido did not disclose the financial terms.
Ownership and handover arrangements
Under the agreed structure, funds managed by IDG Capital will hold 95% of the equity through two special purpose vehicles, while a limited partnership established mainly by SLC's incoming management team will take the remaining 5%. The transaction includes SLC's Beijing factory and its production equipment.
Shiseido will license the intellectual property rights IDG needs to run the business. For a specified period after the transfer, it will also support new product development, provide technical assistance for the stable supply of existing products, and continue supplying raw materials and selected products. Shiseido presents these arrangements as a means of maintaining SLC's innovation capability, product quality and business continuity through the handover.
Rationale: profitability and focus
The sale is part of Shiseido's 2030 Medium-Term Strategy, under which the group is pursuing improved profitability and capital efficiency. Shiseido says it wants to direct management resources toward the areas where it holds the greatest competitive advantage, focusing on priority brands and higher-growth opportunities. It characterises SLC as a business that would require continued investment in product innovation and digital capabilities.
The company also described China as a strategically important and attractive market, one where e-commerce is expanding quickly, consumer behaviour is changing and a more varied set of competitors has emerged.
From joint venture to full ownership to sale
SLC was set up in 1991 as a joint venture with Beijing Liyuan, a subsidiary of Yiqing Group, which is owned by the Beijing Municipal Government. It has sold the C-beauty brand Aupres since 1994. With the joint venture agreement due to expire in December 2026, the partners agreed not to renew it; Shiseido instead bought Beijing Liyuan's 35% stake on September 1, 2026, taking full ownership ahead of the sale.
Timing against recent results
The divestment was announced days after Shiseido reported a 124.3% year-on-year rise in third-quarter 2026 core operating profit to ¥67.5 billion (US$422.13 million). The company attributed the recovery to restructuring, cost reductions and improved margins rather than to strong product demand; like-for-like sales grew 0.7%.
On the strength of those results, Shiseido raised its full-year core operating profit forecast to ¥87 billion (US$546 million) from ¥59 billion (US$433 million).
